Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 1 Issue 12, December 2020

Volume 1 Issue 12

Distinct effects of BRCA1 and BRCA2 mutations on immune-checkpoint therapy

Mutations in BRCA1 and BRCA2 result in distinct mutational genomic landscapes, which leads to differential effects on the tumor immune microenvironment and responses to immune-checkpoint therapy.

See Samstein, Krishna, Ma et al.

Image: Mofei Han, Lemo Creative Studio. Cover Design: Lauren Heslop.

Editorial

  • Editorial |

    As COVID-19 continues to surge, it is essential to understand and address the looming crisis of mental-health issues caused or exacerbated by the pandemic.

News & Views

  • News & Views |

    The response to immunotherapy has been linked to human leukocyte antigen (HLA) genotype in certain cancers. A new study examining the interaction between cancer type–specific mutational exposures and the B44 and B27 HLA supertypes finds that patients with mutant peptides complementary to these supertypes receive the most benefit from immune-checkpoint blockade.

    • Andrea Castro
    • Hannah Carter
  • News & Views |

    Achieving depletion of regulatory T cells while sparing tumor-specific effector T cells has long remained an elusive goal of immunotherapy. A new study describing the development of an antibody to the cytokine receptor CD25 optimized to ensure depletion of regulatory T cells without blocking binding of the cytokine IL-2 will reinvigorate interest in this therapeutic avenue.

    • Gavin I. Ellis
    • James L. Riley

News

Reviews

Research

Search

Quick links